SLC5A2 and hyperlipidemia: Patients in the SGLT2 inhibitor group tended to have more comorbidities, with a significantly higher Charlson Comorbidity Index (2.1 vs. 1.8; P < 0.0001) and higher rates of acute myocardial infarction (9% vs. 5%), congestive heart failure (21% vs. 14%), dyslipidaemia (70% vs. 39%), hyperlipidaemia (69% vs. 39%), hypertension (71% vs. 48%), mild liver disease (23% vs. 12%), nephropathy (10% vs. 4%) and neuropathy (63% vs. 32%; all P < 0.0001).